CEO, Martin Gouldstone Q&A with Vox Markets

Oncimmune’s CEO, Martin Gouldstone, speaks with Paul Hill from Vox Markets about the company’s mission, unique selling points, and how the proprietary ImmunoINSIGHTS autoantibody profiling service supports biopharma companies in developing and monitoring new drugs and precision medicines. He also explores the current market demand landscape, Oncimmune’s breakeven revenue target, and financial visibility through 2025.